Dr. Mitul C. Mehta, MD

Dr. Mehta practices at UCI Health - Orange in Orange, California, part of UC Irvine.

Dr. Mehta's NPI, 1730341181, was assigned on June 26, 2008. Dr. Mehta graduated from Keck School of Medicine of USC in 2008. Dr. Mehta's California license number on file is A130598.

Dr. Mehta's primary practice is UCI Health - Orange, at 101 City Drive South, Orange, CA 92868 in Orange County. The practice phone is (714) 456-7890.

Dr. Mehta's primary practice is UCI Health - Orange in Orange, California, part of UC Irvine. Dr. Mehta is also affiliated with Hoag Hospital Newport Beach. Dmand AI also links Dr. Mehta to 1 more hospital, 3 group practices and clinics and 3 medical groups, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Mehta practices, 6 sites in all. Vendor and product names are available with a free account.

Retina specialist is Dr. Mehta's primary specialty in the NPI Registry, under taxonomy code 207WX0107X. Dr. Mehta is board certified in ophthalmology by the American Board of Ophthalmology. Dmand AI has Dr. Mehta's licenses on file in 4 states: California, Michigan, New York and Ohio.

Dmand AI lists age-related macular degeneration, cataract, cataract surgery with lens implant, conjunctivitis, dry eye, eyelid inflammation, glaucoma and glaucoma surgery among the conditions Dr. Mehta treats.

CMS data shows 6,096 Medicare services from Dr. Mehta across 12 procedure codes in 2024, for 1,074 Medicare patients. Medicare paid $303,204 for them.

CMS counts 1,074 Medicare patients who saw Dr. Mehta in 2024. The largest group is 75 to 84, with 421 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 26% are also on Medicaid. Their average risk score is 1.62, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Mehta's median patient age at 70, with 54% women.

In 2024, Dr. Mehta wrote 488 Medicare Part D claims for 157 patients. 57% of them were for generic drugs. CMS names the drug for 409 of them, across 13 drugs with 11 or more claims each, at $60,521 in total drug cost. In 2023, CMS named 436 claims across 15 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 100 out of 100 for Dr. Mehta for performance year 2024, reported through an alternative payment model (APM). Dr. Mehta accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Cataract surgery: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 21 papers to Dr. Mehta, published from 2014 to 2025. 2019 was the busiest year, with 3. The most frequent topics are Ophthalmology, Retinal Diseases and Vitreoretinal Surgery. Dr. Mehta has published most often in Int Ophthalmol Clin. Dr. Mehta's most frequent co-authors are Angeline Liu Wang, MD, Darren K. Knight, MD and Ronald C. Gentile, MD.

Dmand AI links Dr. Mehta to 1 clinical trial. Conditions studied include Retinitis Pigmentosa and Retinal Dystrophies.

CMS Open Payments shows 332 general payments to Dr. Mehta from 31 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 42% of the total. Novartis Pharmaceuticals Corporation paid the most, $51,260. It also lists 4 research payments totaling $21,613 in 2024.

Dr. Mehta graduated from Keck School of Medicine of USC in 2008.

Dr. Mehta is in network with 14 carriers, including Aetna, Elevance and Blue Cross Blue Shield of Michigan. PPO plans come from the most carriers, 9. Check the plan with the practice before a visit.